What a Strategic Leader Does in a Pre-Revenue Biotech and How to Tell If Yours Is Missing

A company with revenue gets feedback every quarter. A pre-revenue biotech gets feedback in lumps: a financing, a trial read-out, a partner's decision. Between those moments, leadership makes calls without a scoreboard, and the stakes are high. BIO, Informa Pharma Intelligence and QLS Advisors found that only 7.9 percent of drugs entering Phase I between 2011 and 2020 reached approval, and just 28.9 percent cleared Phase II. Cash adds pressure. EY's 2025 Biotech Beyond Borders report found that 39 percent of biotechs assessed in 2024 had under twelve months of cash. With odds that long and runways that short, small strategic errors are rarely forgiven.

Investors see this too. They are backing a team that can decide as much as a molecule. A company with no visible owner of strategy looks like one that will drift between financings.

Titles vary, but the work falls into four jobs.

Connects Science, Capital and Commercial Decisions

Scientists optimise for data quality, finance teams for runway and investors for return. A strategic leader holds those views together. When the team debates a second indication, this person asks what it costs, what evidence it needs, how a payer will see it and whether the round can fund it. Without that translation, each function makes reasonable choices that do not add up.

Owns the Asset's Value Story

Every programme needs a clear target product profile: who the patients are, what the product must show against current care, and what price and access it can support. The strategic leader builds that profile and revisits it as data arrives. It becomes the reference point for trial design, partnering and fundraising, and it keeps the company honest about which assets deserve the next dollar.

Sequences Spend Against Milestones

Pre-revenue companies live on milestone-based plans. This person decides which studies come first, which wait, and what each costs against the runway. That includes saying no to promising work that does not move the next inflection point. It is an uncomfortable part of the job, and one reason scientific founders often prefer to hand it to someone else.

Leads the Outside Conversations

Investors, pharma partners, advisers and sometimes payers all form views of the company, and those views need to match. A strategic leader makes sure the story told to a venture fund this month agrees with the one told to a partner next month, and that feedback from either returns to the plan. Our piece on capital raising mistakes before Series A shows how quickly inconsistent narratives cost founders leverage.

Strategic Leader, CEO or Senior Management Executive: What Is the Difference?

A strategic leader describes a function, not a job title. Sometimes the CEO fills it. In other companies it sits with a chief business officer, chief commercial officer or another senior management executive. Trouble starts when a scientist founder serves as CEO and the strategic function is assumed to belong to someone else. Then nobody owns the integrated plan, and the board only notices when a financing stalls. So the practical test is not who holds the title but who can explain the plan for the next 24 months, defend its assumptions and say what would change it. If that person exists, you have the function. If the answer is "the board, collectively," you probably do not.

The gap rarely announces itself. It shows up as friction in three places.

In the Boardroom

Board decks report activity, not decisions. Directors ask the same questions meeting after meeting because nobody owns the answer. Budget conversations start from last quarter's spend instead of the next milestone. If your board has to build the strategy itself, you probably do not have someone running it.

In the Pipeline

Programme choices follow scientific interest or the most recent paper. Indications are picked before anyone has looked at market size, competing treatments or how payers might judge the evidence. Commercial questions get deferred until late-stage data, by which time the trial design that would answer them is already fixed. A strategic leader would have raised those questions two years sooner.

In Fundraising and Partnering

Pitches change from one investor meeting to the next. The financial model and the scientific plan disagree. Partnering conversations are reactive, triggered by inbound interest rather than by a plan for what the company needs from a partner.

A Three-Question Test

Ask three board members, separately, what the company must achieve in the next 18 months and why. Then ask what would make the plan change. If the answers differ, or nobody can name the trigger for a change, the gap is real, and it is cheaper to fix now than after the next financing falls short.

What to Do Once You Recognise the Gap

Naming the gap is the first step. Filling it is the second, and the right option depends on stage.

Stretch the Existing Team

If a current executive has the appetite and relevant experience, give them explicit ownership of the integrated plan, with a defined mandate and a board sponsor. This costs the least, but it only works if the person has time and credibility with investors.

Hire a Senior Management Executive

A full-time hire suits companies with a financed plan and enough scope to keep a seasoned leader busy, such as a company preparing for clinical data or a major raise. Be specific in the brief: milestone ownership, board reporting and partnering responsibilities, not just a title.

Bring in Fractional or Interim Leadership

Earlier companies often need senior judgement without a full salary and a full seat on the executive team. A fractional or interim strategic leader can build the plan, sharpen the investor story and prepare the ground for a permanent hire. We compare the trade-offs in our guide to fractional and full-time CCOs, which picks up where this article leaves off.

What Changes When the Role Is Filled

Companies that fill the gap tend to notice three things. Decisions move faster because someone owns them. Investor conversations get easier because the plan, model and story agree. And the board shifts from managing the company to advising it. Because strategy is cheapest to change early, the first 90 days matter most: a diagnosis of where the plan stands, a milestone-based plan with a runway model, and a short list of decisions that cannot wait.

How Illumination Strategy Supports Biotech Leadership

Illumination Strategy works with pre-revenue life sciences companies on exactly this gap. That runs from a short leadership and plan review to interim strategic leadership on milestone planning, investor positioning and commercial readiness. If you suspect your company is missing a strategic leader, start with a conversation about your next 24 months. The answer to who owns that plan will tell you most of what you need.

What is a strategic leader in a biotech company?

A strategic leader is the person who owns the integrated plan connecting science, capital, regulatory path and commercial value. In a pre-revenue biotech, that means deciding which asset to advance, which indication to pursue and how to fund each milestone. The title varies. The function is what matters: someone accountable for how the whole company wins.

Is a strategic leader the same as a CEO?

Sometimes, but not automatically. A CEO holds final accountability, yet many founder CEOs spend their time on science, fundraising logistics or operations and leave integrated strategy unowned. A strategic leader may be the CEO, a chief business or commercial officer, or another senior executive. What matters is that one named person owns the plan and defends it to the board.

When does a pre-revenue biotech need a strategic leader?

Before key decisions become expensive to reverse. That usually means ahead of indication selection, pivotal trial design or a major financing, often 18 to 36 months before an expected inflection point. Waiting until the data arrives wastes the period when strategy has the most influence on cost, evidence requirements and investor interest.

What does a senior management executive do in a pre-revenue biotech?

A senior management executive sets priorities across functions, builds the milestone-based plan and budget, manages board and investor communication, and leads partnering discussions. They also bring commercial and market access thinking into development decisions early, so the company does not discover payer or market problems after the pivotal trial has already been designed.

What are the signs a biotech lacks strategic leadership?

Common signs include board decks that report activity but not decisions, pipeline choices driven only by scientific interest, investor pitches that change between meetings, and commercial questions deferred until late-stage data. Slow decisions with no clear owner, and repeated surprises on timelines or cash, also suggest that nobody is steering across functions.

Can a scientist founder act as the strategic leader?

Yes, some can, particularly those who have run companies before. But the two jobs pull in different directions: deep scientific work needs focus, while integrated strategy needs constant outward attention. Many scientist founders do best when they pair with a business-minded leader who owns planning, capital and partnerships while they lead the science.

Should a pre-revenue biotech hire full-time or fractional leadership?

Full-time hires suit companies with enough scope, funding and complexity to keep a senior executive fully engaged. Fractional or interim leaders suit earlier companies that need seasoned judgement without a permanent salary. The right answer depends on stage, runway and workload. We cover the trade-offs in our comparison of fractional and full-time commercial leadership.

How does a strategic leader help with fundraising?

A strategic leader turns the science into a funding case: the milestone, the cost, the evidence investors need and the value at each step. That consistency makes investor conversations sharper and reduces mismatched rounds. They also keep the data room, financial model and story aligned, which helps diligence move faster.

What should the first 90 days of a new strategic leader look like?

Start with listening and diagnosis. In the first 90 days, review the asset and evidence, interview board members and key staff, and test assumptions with a few investors or partners. Then produce a milestone-based plan, a runway model and a clear decision list. Early wins come from clarity, not from adding activity.